Emulate
Emulate, Inc. is a leading company that commercialized the Human Emulation System, an advanced microfluidic platform originating from Harvard’s Wyss Institute, to create Organ-on-a-Chip (OOC) systems. This technology enables researchers to precisely replicate the complex mechanical and biochemical functions of human organs on a microchip, including models for the liver, lung, kidney, brain, and intestine. By simulating realistic cellular microenvironments and dynamic fluid flow within microfluidic channels, Emulate’s OOC systems provide highly predictive and physiologically relevant models for drug toxicity testing, disease modeling, and efficacy studies. Their platform delivers reliable, human-predictive data, positioning it as one of the most validated and adopted solutions in pharma R&D. Emulate actively collaborates with regulatory bodies like the FDA—even securing the first and only Organ-Chip accepted into the ISTAND program for DILI evaluation—and major pharmaceutical companies to integrate this powerful platform into the drug discovery pipeline, thereby accelerating preclinical testing, reducing reliance on traditional animal models, and speeding the development of safer therapies.
Latest Market Research Report on Organ-on-Chip Download PDF Brochure Now
MIMETAS B.V.
MIMETAS B.V. is a key player in the organ-on-a-chip industry, distinguished by its innovative OrganoPlate® platform. This technology allows scientists to culture 3D human tissues with controlled perfusion in a high-throughput, lab-friendly format that is compatible with standard laboratory equipment. The OrganoPlate enables researchers to scale up experiments and run multiple organ models in parallel without requiring complex additional hardware. This platform is extensively utilized for high-throughput drug screening, toxicity assessment, and sophisticated disease modeling. MIMETAS offers specialized models, such as the blood-brain barrier-on-a-chip, which is crucial for neurological drug development. By providing pre-seeded and non-seeded organ-on-chip models, MIMETAS supports robust 3D tissue modeling and personalized medicine initiatives, advancing complex multi-organ system studies. The company’s focus on accessibility and scalability makes it a practical choice for pharmaceutical companies and academic research institutions looking to integrate OOC systems directly into their established screening pipelines.
CN Bio Innovations Ltd
CN Bio Innovations Ltd is a UK-based leader in microphysiological systems, renowned for its PhysioMimix® OOC Microphysiological System. This platform specializes in recreating 3D human organs in the laboratory to provide high-fidelity, human-relevant data, especially critical for predicting metabolic behavior and toxicity in early drug development. CN Bio’s deep expertise focuses on liver-focused and multi-organ systems, such as the Liver-on-a-chip and Gut/Liver-on-a-chip models, which are essential for understanding drug actions and metabolic pathways. The company aims to facilitate a quicker and more cost-effective drug discovery process while minimizing the reliance on animal testing. Recent developments include expanding collaboration with the US FDA to evaluate multi-organ microphysiological systems and launching the PhysioMimix Core, an all-in-one OOC system capable of handling single-organ, multi-organ, and high-throughput configurations. Through strategic partnerships, such as one with Altis Biosystems to develop a next-generation human gut/liver model, CN Bio continues to enhance the predictive accuracy for ADME (absorption, distribution, metabolism, and excretion) studies, cementing its position as a reliable partner in translational research.
InSphero AG
InSphero AG is recognized for its expertise in three-dimensional microtissue engineering, integrating OOC technology with robust 3D spheroid and organoid models. The company’s flagship system, the Akura™ Flow platform, is designed as a plug-and-play solution that seamlessly incorporates microfluidic channels to maintain physiologically relevant conditions for organoids. This approach enables the creation of scaffold-free human tissues suitable for high-throughput screening and toxicology studies. InSphero’s models, including liver-on-a-chip and pancreatic islet models, are pivotal in research related to drug-induced liver injuries, metabolic diseases, and diabetes. The Akura™ Flow system simplifies the scaling of multi-tissue studies, offering a practical alternative to complex setups. By providing integrative platforms for drug safety and efficacy assessments, InSphero reinforces its reputation for delivering robust, scalable solutions in the organ-on-a-chip space, driving scientific advancements in personalized medicine and fundamental biological research.
TissUse GmbH
TissUse GmbH is a prominent player in the Organ-on-Chip market, specializing in the development of multi-organ-chip platforms. The company’s focus on true multi-organ integration, rather than just single-organ models, distinguishes its offering. Its key product, the HUMIMIC platform, allows researchers to connect multiple human tissues on a single microfluidic chip. This capability is crucial for studying systemic interactions, complex disease mechanisms, and accurately modeling ADME (Absorption, Distribution, Metabolism, and Excretion) behavior. TissUse’s modular designs support integrated pharmacokinetic and pharmacodynamic assessments, which are essential for advanced translational models in preclinical validation and toxicity testing. By replicating complex cross-organ dynamics, TissUse provides deeper physiological relevance and more predictive human data than most competitors, propelling its adoption among researchers who require comprehensive assessment of drug candidates traveling through the body.
Hesperos, Inc.
Hesperos, Inc. accelerates drug discovery by offering advanced Human-on-a-Chip® microfluidic systems. These comprehensive systems are utilized to provide critical safety and efficacy data for novel therapeutics intended for the pharmaceutical, cosmetic, and food industries. Hesperos specializes in creating functional, interconnected human organ systems in vitro, allowing for advanced toxicology testing and drug efficacy evaluation that closely mimics in vivo conditions. The company focuses on continuous innovation within the OOC technology space, evidenced by its engagement in research initiatives, such as receiving grants from the NIH to advance Alzheimer’s research. Hesperos’s platforms are scalable and designed for personalized medicine applications, enabling researchers to predict human response to drugs with greater accuracy. By providing robust microfluidic solutions for systemic studies, Hesperos plays a key role in reducing development timelines and enhancing the safety profile of emerging therapeutic products.
AxoSim LLC
AxoSim LLC is dedicated to advancing nerve-on-a-chip technology, offering a 3D cell-based model that accurately mimics the function and behavior of human nerves. Established in New Orleans, the company specializes in creating in vitro systems to improve drug development, particularly for neural and neuromuscular diseases. AxoSim’s platforms facilitate detailed neurotoxicity, neuroregeneration, and efficacy studies, providing researchers with unprecedented insights into complex neural circuits. Their technology addresses critical areas like Neurodegenerative disease models, Myelination models, and Peripheral neuropathy. By supporting both commercial and academic research teams, AxoSim helps the industry gain a deeper understanding of neural circuit function using highly predictive in vitro systems, bridging the gap between traditional cell culture and complex in vivo testing methods for safer and more effective neurological therapies.
Latest Market Research Report on Organ-on-Chip Download PDF Brochure Now